Rick Doblin reflects on 38 years of MAPS, discussing psychedelic milestones and obstacles. Lykos Therapeutics submits NDA for MDMA-assisted therapy for PTSD in December 2023.
Rick Doblin
MAPS completes Phase 3 study for MDMA-AT in PTSD treatment, marking historic milestone in psychedelic drug research. Safety and efficacy of MDMA-assisted therapy still under investigation.
Keren Tzarfaty, Michael Mithoefer, Julie Holland